Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Maintenance Zanzalintinib With Oral Etoposide Following High-dose Chemotherapy in Patients With Relapsed Metastatic Germ-cell Tumor

NCT06937866 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT06937866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06937866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Maintenance Zanzalintinib With Oral Etoposide Following High-dose Chemotherapy in Patients With Relapsed Metastatic Germ-cell Tumor
Lead sponsor
Indiana University
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 12, 2025
Completion date
September 30, 2031
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

germ cell tumor